Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark

References

• www.UNAIDS.org.
   Google Scholar
• Sharland M, Gibb DM, Tudor-Williams G. Advances in the prevention and treatment of paediatric HIV infection in the United Kingdom. Sex Transm Inf 2003; 79: 53–5
   PubMed Web of Science ®Google Scholar
• Martino, MD, Tovo, PA, Balducci, M, Galli, L, Gabiano, C, Rezza, G, Pezzotti, P, for the Italian Register for HIV Infection in Children and the Italian National AIDS Registry. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000;284:190–7.
   PubMedGoogle Scholar
• Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, et al. for the Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345: 1522–8
   PubMed Web of Science ®Google Scholar
• Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, et al. on behalf of the National Study of HIV in Pregnancy and Childhood and the Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Br Med J 2003; 327: 1019–24
   PubMed Web of Science ®Google Scholar
• Fraaij PL, van Kampen JJ, Burger DM, de Groot R. Pharmacokinetics of antiretroviral therapy in HIV-1-infected children. Clin Pharmacokinet 2005; 44: 935–56
   PubMedGoogle Scholar
• Resino S, Bellón JM, Gurbindo D, Ramos JT, León JA, Mellado MJ, Muñoz-Fernández MA. Viral load and CD4+ T-lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus 1-infected children: an observationial study. Clin Infect Dis 2003; 37: 1216–25
   PubMedGoogle Scholar
• Resino S, Bellón JM, Resine R, Navarro ML, Ramos JT, De José MI, Muñoz-Fernández MA. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis 2004; 38: 1605–12
   PubMedGoogle Scholar
• Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatric Infect Dis J 1999; 18: 682–9
   PubMed Web of Science ®Google Scholar
• Gould Chadwick E, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, et al. PACTG Protocol 345 Team. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J 2005; 24: 793–800
   PubMedGoogle Scholar
• Resino S, Resino R, Micheloud D, Gutierrez DG, Leon JA, Ramos JT, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 y of follow-up. Clin Infect Dis 2006; 42: 862–9
   PubMed Web of Science ®Google Scholar
• Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, et al. Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Ped Infect Dis J 2006; 25: 420–6
   PubMedGoogle Scholar
• www.statestikbanken.dk.
   Google Scholar
• Schmid J, Jensen–Fangel S, Valerius NH, Nielsen VR, Christensen HO, Nielsen H, Obel N. Demographics in HIV-infected children in Denmark: results from the Danish Paediatric HIV Cohort Study. Scand J Infect Dis 2005; 37: 344–9
   PubMed Web of Science ®Google Scholar
• Sharland M, Blance S, Castelli G, Ramos J, Gibb DM, PENTA Steering Committeei. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5(Suppl 2)61–86
   PubMed Web of Science ®Google Scholar
• Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35: 1541–8
   PubMed Web of Science ®Google Scholar
• Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, et al. for the Pediatric AIDS Clinical Trials Group 382 Team. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999; 341: 1874–81
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E, et al. 48-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 216–23
   PubMed Web of Science ®Google Scholar
• Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, et al. for the Pediatric AIDS Clinical Trials Group 338 Study Team. Nucleoside analogues plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children. A randomized controlled trial. JAMA 2000; 283: 492–8
   PubMedGoogle Scholar
• Faye A, Bertone C, Teglas JP, Chaix ML, Douard D, Firtion G, et al. for the French Perinatal Study. Early multitherapy including a protease inhibitor for human immunodeficiency virus type-1-infected infants. Pediatr Infect Dis J 2002; 21: 518–25
   PubMedGoogle Scholar
• Krogstad P, Lee S, Johnson G, Stanley K, MaNamara J, Moye J, et al. and the Pediatric AIDS Clinical Trials Group 377 Study Team. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002; 34: 991–1001
   PubMed Web of Science ®Google Scholar
• Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomized trial. Lancet 2002; 359: 733–40
   PubMed Web of Science ®Google Scholar
• King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, et al. Efficacy, tolerability and pharmacokinetics of 2 nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents. Peadiatric AIDS Clinical Trials Group Protocol 403. Pediatr Infect Dis J 2005; 24: 880–5
   PubMedGoogle Scholar
• Reddington C, Cohen J, Baldillo A, Toye M, Smith D, Kneut C, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000; 19: 1148–53
   PubMed Web of Science ®Google Scholar
• Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandström E. Treatment history and baseline viral load, but not viral tropism CCR-5 genotype, influenced prolonged antiviral efficacy of highly active antiretroviral therapy. AIDS 1998; 12: 2193–202
   PubMed Web of Science ®Google Scholar
• European Collaborative Study. Age-related standards for total lymphocyte, CD4+ and CD8+ cell counts in children born in Europe. Pediatr Infect Dis J 2005; 24: 595–600
   PubMed Web of Science ®Google Scholar
• Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 y of age: The Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112: 973–80
   PubMed Web of Science ®Google Scholar
• Granados JMS, Amador JTR, De Miguel SF, Tomé MIG, Conejo PR, Vivas PF, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 863–7
   PubMedGoogle Scholar
• Viani RM, Araneta MRG, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 725–31
   PubMed Web of Science ®Google Scholar
• van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, et al. Reported adherence as a determinator of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002; 109: 61
   PubMed Web of Science ®Google Scholar